{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T22:39:41Z","timestamp":1784932781785,"version":"3.55.0"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Affective Disorders"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.jad.2025.120562","type":"journal-article","created":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T19:02:36Z","timestamp":1761591756000},"page":"120562","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"PA","title":["Retrospective multicenter cohort study of slow titration of vortioxetine to mitigate early nausea in major depression"],"prefix":"10.1016","volume":"394","author":[{"given":"Andrea","family":"Fagiolini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Aguglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emi","family":"Bondi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debora","family":"Bussolotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Caldiroli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Carmellini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Clerici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico","family":"De Berardis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"De Filippis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Despoina","family":"Koukouna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Libri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Menculini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Pardossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Pinzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrice","family":"Rescalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfonso","family":"Tortorella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giada","family":"Trovini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Cuomo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jad.2025.120562_bb0005","first-page":"375","article-title":"Slow versus standard up-titration of paroxetine for the treatment of depression in cancer patients: a pilot study","volume":"20","author":"Amodeo","year":"2012","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.jad.2025.120562_bb0010","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1177\/0269881116628440","article-title":"The safety and tolerability of vortioxetine: analysis of data from randomized placebo-controlled trials and open-label extension studies","volume":"30","author":"Baldwin","year":"2016","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.jad.2025.120562_bb0015","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.jad.2022.05.098","article-title":"Efficacy and safety of vortioxetine in treatment of patients with major depressive disorder and common co-morbid physical illness","volume":"311","author":"Baldwin","year":"2022","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2025.120562_bb0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.110532","article-title":"Activation of the 5-HT7 receptor and MMP-9 signaling module in the hippocampal CA1 region is necessary for the development of depressive-like behavior","volume":"38","author":"Bijata","year":"2022","journal-title":"Cell Rep."},{"key":"10.1016\/j.jad.2025.120562_bb0025","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1177\/0269881112441866","article-title":"A randomized clinical study of Lu AA21004 in the prevention of relapse in patients with major depressive disorder","volume":"26","author":"Boulenger","year":"2012","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.jad.2025.120562_bb0030","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1111\/j.1440-1819.2010.02136.x","article-title":"Slow vs standard up-titration of paroxetine in the treatment of panic disorder: a prospective randomized trial","volume":"64","author":"Buoli","year":"2010","journal-title":"Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.jad.2025.120562_bb0035","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1017\/S1092852919000786","article-title":"Long-term functioning outcomes are predicted by cognitive symptoms in working patients with major depressive disorder treated with vortioxetine: results from the AtWoRC study","volume":"24","author":"Chokka","year":"2019","journal-title":"CNS Spectr."},{"key":"10.1016\/j.jad.2025.120562_bb0040","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1017\/S1092852921000936","article-title":"Vortioxetine 20 mg\/day in patients with major depressive disorder: updated analysis of efficacy, safety, and optimal timing of dose adjustment","volume":"28","author":"Christensen","year":"2023","journal-title":"CNS Spectr."},{"key":"10.1016\/j.jad.2025.120562_bb0045","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1080\/14737175.2024.2333394","article-title":"Perspectives on the impact of vortioxetine on the treatment armamentarium of major depressive disorder","volume":"24","author":"Cuomo","year":"2024","journal-title":"Expert. Rev. Neurother."},{"key":"10.1016\/j.jad.2025.120562_bb0050","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s12991-024-00505-1","article-title":"Individualized strategies for depression: narrative review of clinical profiles responsive to vortioxetine","volume":"23","author":"Cuomo","year":"2024","journal-title":"Ann. General Psychiatry"},{"key":"10.1016\/j.jad.2025.120562_bb0055","first-page":"36","article-title":"Vortioxetine (brintellix): a new serotonergic antidepressant","volume":"40","author":"D\u2019Agostino","year":"2015","journal-title":"P T."},{"key":"10.1016\/j.jad.2025.120562_bb0060","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1590\/1516-4446-2019-0690","article-title":"Adjunctive vortioxetine for SSRI-resistant major depressive disorder: a \u201creal-world\u201d chart review study","volume":"42","author":"De Berardis","year":"2020","journal-title":"Braz J Psychiatry."},{"key":"10.1016\/j.jad.2025.120562_bb0065","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1177\/02698811231216320","article-title":"Clinical benefits and bioequivalence of vortioxetine oral drop solution versus oral tablets","volume":"38","author":"Fagiolini","year":"2024","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.jad.2025.120562_bb0070","series-title":"Trintellix (Vortioxetine)","author":"Food and Drug Administration (FDA)","year":"2018"},{"key":"10.1016\/j.jad.2025.120562_bb0075","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1007\/s40263-025-01207-2","article-title":"Effectiveness and tolerability of Vortioxetine Oral drops versus Oral tablets in major depressive disorder: an analysis of a real-world cohort study in Switzerland","volume":"39","author":"Hochstrasser","year":"2025","journal-title":"CNS Drugs"},{"key":"10.1016\/j.jad.2025.120562_bb0080","doi-asserted-by":"crossref","first-page":"33","DOI":"10.64719\/pb.4567","article-title":"Efficacy and tolerability of two different kinds of titration of paroxetine hydrocloride solution: an observational study","volume":"48","author":"Ielmini","year":"2018","journal-title":"Psychopharmacol. Bull."},{"key":"10.1016\/j.jad.2025.120562_bb0085","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1017\/S1461145712000727","article-title":"A randomized, double-blind, placebo-controlled 6-wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorder*","volume":"16","author":"Jain","year":"2013","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.jad.2025.120562_bb0090","article-title":"Comorbidity within mental disorders: a comprehensive analysis based on 145 990 survey respondents from 27 countries","volume":"29","author":"JJ","year":"2020","journal-title":"Epidemiol. Psychiatr. Sci."},{"key":"10.1016\/j.jad.2025.120562_bb0095","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/ijnp\/pyad018","article-title":"Effectiveness and safety of Vortioxetine for the treatment of major depressive disorder in the real world: a systematic review and Meta-analysis","volume":"26","author":"Li","year":"2023","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.jad.2025.120562_bb0100","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1007\/s00213-014-3839-0","article-title":"A randomized, double-blind, duloxetine-referenced study comparing efficacy and tolerability of 2 fixed doses of vortioxetine in the acute treatment of adults with MDD","volume":"232","author":"Mahableshwarkar","year":"2015","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.jad.2025.120562_bb0105","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2025.1617345","article-title":"Efficacy and tolerability of vortioxetine monotherapy in SSRI-resistant OCD: a retrospective multicenter study","volume":"16","author":"Martiadis","year":"2025","journal-title":"Front. Psychiatry"},{"key":"10.1016\/j.jad.2025.120562_bb0110","doi-asserted-by":"crossref","DOI":"10.1038\/s41572-023-00454-1","article-title":"Major depressive disorder","volume":"9","author":"Marx","year":"2023","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.jad.2025.120562_bb0115","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1016\/S0149-2918(03)80220-5","article-title":"Tolerability and adherence issues in antidepressant therapy","volume":"25","author":"Masand","year":"2003","journal-title":"Clin. Ther."},{"key":"10.1016\/j.jad.2025.120562_bb0120","article-title":"Effectiveness of Vortioxetine in patients with major depressive disorder in real-world clinical practice: results of the RELIEVE study","volume":"13","author":"Mattingly","year":"2022","journal-title":"Front. Psychol."},{"key":"10.1016\/j.jad.2025.120562_bb0125","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2023.1075939","article-title":"Safety and effectiveness of vortioxetine for major depressive disorder: real-world evidence from a population-based study in South Korea","volume":"14","author":"Moon","year":"2023","journal-title":"Front. Psychiatry"},{"key":"10.1016\/j.jad.2025.120562_bb0130","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1111\/cns.12247","article-title":"Interplay between serotonin 5- HT 1A and 5- HT 7 receptors in depressive disorders","volume":"20","author":"Naumenko","year":"2014","journal-title":"CNS Neurosci. Ther."},{"key":"10.1016\/j.jad.2025.120562_bb0135","doi-asserted-by":"crossref","first-page":"e1480","DOI":"10.4088\/JCP.13097TX1C","article-title":"Residual symptoms in depression: prevalence and impact","volume":"76","author":"Nierenberg","year":"2015","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2025.120562_bb0140","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1002\/hup.2433","article-title":"Benefit of slow titration of paroxetine to treat depression in the elderly","volume":"29","author":"Olgiati","year":"2014","journal-title":"Hum. Psychopharmacol."},{"key":"10.1016\/j.jad.2025.120562_bb0145","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.3390\/jcm11082129","article-title":"Polypharmacotherapy in psychiatry: global insights from a rapid online survey of psychiatrists","volume":"11","author":"Ordak","year":"2022","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.jad.2025.120562_bb0150","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1186\/s12888-022-04109-5","article-title":"Real-world effectiveness of vortioxetine in outpatients with major depressive disorder: functioning and dose effects","volume":"22","author":"Papalexi","year":"2022","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.jad.2025.120562_bb0155","doi-asserted-by":"crossref","first-page":"431","DOI":"10.31887\/DCNS.2008.10.4\/espaykel","article-title":"Partial remission, residual symptoms, and relapse in depression","volume":"10","author":"Paykel","year":"2008","journal-title":"Dialogues Clin. Neurosci."},{"key":"10.1016\/j.jad.2025.120562_bb0160","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1515\/revneuro-2012-0082","article-title":"5-HT1A receptor as a key player in the brain 5-HT system","volume":"0","author":"Popova","year":"2013","journal-title":"Rev. Neurosci."},{"issue":"Suppl. 17","key":"10.1016\/j.jad.2025.120562_bb0165","first-page":"14","article-title":"Tolerability and patient compliance","volume":"60","author":"Roose","year":"1999","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2025.120562_bb0170","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.pharmthera.2014.07.001","article-title":"Vortioxetine, a novel antidepressant with multimodal activity: review of preclinical and clinical data","volume":"145","author":"Sanchez","year":"2015","journal-title":"Pharmacol Ther. England"},{"key":"10.1016\/j.jad.2025.120562_bb0175","doi-asserted-by":"crossref","first-page":"451","DOI":"10.3390\/ph14050451","article-title":"Withdrawal symptoms following discontinuation of Vortioxetine\u2014retrospective chart review","volume":"14","author":"Siwek","year":"2021","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.jad.2025.120562_bb0180","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.852042","article-title":"Case report: Vortioxetine in the treatment of depressive symptoms in patients with epilepsy\u2014case series","volume":"13","author":"Siwek","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.jad.2025.120562_bb0185","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.euroneuro.2016.03.007","article-title":"A meta-analysis of randomized, placebo-controlled trials of vortioxetine for the treatment of major depressive disorder in adults","volume":"26","author":"Thase","year":"2016","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.jad.2025.120562_bb0190","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.jad.2022.02.002","article-title":"Vortioxetine 5, 10, and 20 mg significantly reduces the risk of relapse compared with placebo in patients with remitted major depressive disorder: the RESET study","volume":"303","author":"Thase","year":"2022","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2025.120562_bb0195","doi-asserted-by":"crossref","first-page":"711","DOI":"10.2174\/1570159X18666200818195720","article-title":"RisksAssociated with Vortioxetine in the established therapeutic indication","volume":"19","author":"Verma","year":"2021","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.jad.2025.120562_bb0200","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.jclinepi.2007.11.008","article-title":"The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"61","author":"Von Elm","year":"2008","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.jad.2025.120562_bb0205","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1002\/da.21952","article-title":"The association between antidepressant dosage titration and medication adherence among patients with depression: Antidepressant titration and medication adherence","volume":"29","author":"Wu","year":"2012","journal-title":"Depress. Anxiety"}],"container-title":["Journal of Affective Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016503272502004X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016503272502004X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T08:51:48Z","timestamp":1780822308000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016503272502004X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":41,"alternative-id":["S016503272502004X"],"URL":"https:\/\/doi.org\/10.1016\/j.jad.2025.120562","relation":{},"ISSN":["0165-0327"],"issn-type":[{"value":"0165-0327","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Retrospective multicenter cohort study of slow titration of vortioxetine to mitigate early nausea in major depression","name":"articletitle","label":"Article Title"},{"value":"Journal of Affective Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jad.2025.120562","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"120562"}}